Cantor Fitzgerald lowered the firm’s price target on ALX Oncology to $18 from $22 and keeps an Overweight rating on the shares. ALX Oncology reported Q2 results, with the big update being the discontinuation of evorpacept’s studies in MDS and AML, based on internal data, the analyst tells investors in a research note. The decision to discontinue came was not a surprise, and the firm doesn’t expect the stock to trade down meaningfully.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ALXO:
- ALX Oncology price target lowered to $16 from $30 at H.C. Wainwright
- ALX Oncology reports Q2 EPS (84c), consensus (88c)
- ALX Oncology Reports Second Quarter 2023 Financial Results and Provides Clinical Program Update
- ALX Oncology receives orphan drug designation from EC for evorpacept
- ALX Oncology Receives Orphan Drug Designation from the European Commission for Evorpacept for the Treatment of Patients with Gastric Cancer